Table 1. Muscle and heart weights in sorafenib-treated tumour-bearing mice.
| Tumour model | Muscle | Experimental groups | |||
| C | T | T Sor | ANOVA | ||
| C26 | GSN | 562±9 c | 445±17 a | 500±15 b | 0,000 |
| Tibialis | 192±3 c | 149±7 a | 168±6 b | 0,000 | |
| Heart | 502±15 b | 439±14 a | 477±16 ab | 0,025 | |
| B16 | GSN | 634±21 b | 522±24 a | 565±17 a | 0,010 |
| Tibialis | 193±8 b | 166±8 a | 178±8 ab | 0,073 | |
| Heart | 586±31 | 514±21 | 512±25 | ns | |
| LLC | GSN | 551±16 c | 390±18 a | 468±7 b | 0,000 |
| Tibialis | 189±9 b | 138±6 a | 157±11 a | 0,005 | |
| Heart | 550±35 | 536±27 | 551±11 | ns | |
Results are mean ± S.E.M. Muscle weights are expressed as mg/100 g of initial body weight. GSN: gastrocnemius muscle. C: animals without tumour (n = 6); T: tumour-bearing animals (n = 8); T Sor: tumour-bearing animals treated with sorafenib (n = 8). Values significantly different of the results by one-way analysis of variance (ANOVA), statistically significant differences by post hoc Duncan test. Different letters in superscript indicate significant differences between groups.